Patent ID: 8299081
Filing Date: 2012-10-30
Classification: A61K,A61P

Abstract:
1. A method of treating drug-resistant cancer comprising administering to a drug-resistant cancer subject in need thereof, a compound of formula II, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the compound, the salt of the tautomer, or the mixture, by inhibiting a cytoplasmic tyrosine kinase or a receptor tyrosine kinase comprising a mutant gatekeeper residue in the subject, wherein the kinase is ABL, KIT, PDGFRa, EGFR, or FLT3, and wherein the cancer is resistant to an anti-cancer drug selected from the group consisting of imatinib mesylate, BAY43-9006, Brostallicin, erlotinib, gefitinib, and vatalanib, and further wherein the compound of formula II has the following formula: wherein R